Your browser is no longer supported. Please, upgrade your browser.
UTHR United Therapeutics Corporation weekly Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E10.06 EPS (ttm)15.17 Insider Own0.10% Shs Outstand42.63M Perf Week-9.31%
Market Cap6.50B Forward P/E12.76 EPS next Y11.95 Insider Trans-59.86% Shs Float39.06M Perf Month-2.82%
Income713.70M PEG- EPS next Q3.49 Inst Own94.00% Short Float14.66% Perf Quarter16.07%
Sales1.60B P/S4.07 EPS this Y19.90% Inst Trans-2.79% Short Ratio9.77 Perf Half Y23.73%
Book/sh44.02 P/B3.46 EPS next Y-16.75% ROA31.80% Target Price134.75 Perf Year23.19%
Cash/sh24.65 P/C6.19 EPS next 5Y-2.30% ROE39.40% 52W Range97.52 - 169.89 Perf YTD6.33%
Dividend- P/FCF10.83 EPS past 5Y33.00% ROI38.40% 52W High-10.23% Beta1.39
Dividend %- Quick Ratio4.00 Sales past 5Y16.60% Gross Margin95.50% 52W Low56.39% ATR4.87
Employees750 Current Ratio4.30 Sales Q/Q1.00% Oper. Margin66.40% RSI (14)43.11 Volatility4.45% 2.77%
OptionableYes Debt/Eq0.00 EPS Q/Q15.70% Profit Margin44.60% Rel Volume1.49 Prev Close146.71
ShortableYes LT Debt/Eq0.00 EarningsFeb 22 BMO Payout0.00% Avg Volume585.98K Price152.51
Recom2.70 SMA20-5.94% SMA50-0.32% SMA20019.56% Volume872,579 Change3.95%
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Feb-25-17 01:04PM  UNITED THERAPEUTICS CORP Financials
Feb-24-17 02:06PM  Vertex Expects Modest Revenue Growth in This
Feb-23-17 05:39PM  United Therapeutics feels squeeze from increased pulmonary hypertension competition at bizjournals.com
11:36AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
10:15AM  United Therapeutics downgraded by Ladenburg Thalmann
09:18AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
09:03AM  United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
Feb-22-17 05:08PM  Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation at Motley Fool -12.47%
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
06:43AM  United Therapeutics beats 4Q profit forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:08AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report
06:00AM  United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results PR Newswire
Feb-15-17 06:00AM  United Therapeutics Corporation To Report Fourth Quarter And Annual 2016 Financial Results Before The Market Opens On Wednesday, February 22, 2017 PR Newswire
Feb-07-17 02:39PM  Your Guide To 2017's Emerging Pharmaceuticals Catalysts
Feb-03-17 06:27AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Jan-30-17 06:06AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi
Jan-11-17 11:10PM  D.C.-area biotech stocks fall on Trump's tough talk on industry at bizjournals.com -6.35%
03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-05-17 08:27AM  New Strong Buy Stocks for January 5th
06:00AM  United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-16 01:14PM  Vertex Pharmaceuticals Expects Strong Revenue Growth in 2016
10:10AM  United Therapeutics' PAH Suite Bodes Well, Competition Rife
09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver?
07:36AM  United Therapeutics Robust Research Pipeline
Dec-28-16 02:05PM  United Therapeutics: Will Orenitram See Strong Patient Demand?
12:35PM  United Therapeutics: Why Tyvaso Is Still a Key Growth Driver
10:55AM  Why United Therapeutics Expects Strong Revenue Growth
Dec-16-16 10:35AM  Dupixent Is Being Explored for Multiple Indications in 2016
Dec-12-16 04:21PM  The 3 Most Profit-Friendly Biotech Stocks at Motley Fool +5.51%
Dec-07-16 05:07PM  Are there buying opportunities in health care?
Dec-02-16 08:05AM  NBIX Continues to Study Valbenazine for Tourette Syndrome
04:29AM  Hedge Funds Are Selling Patterson Companies, Inc. (PDCO) at Insider Monkey
Dec-01-16 02:25PM  Pig organs to save lives by end of decade: United Therape...
11:32AM  Hedge Funds Are Buying WellCare Health Plans, Inc. (WCG) at Insider Monkey
Nov-30-16 11:17AM  What Happens When Your Biotech Stock Faces Generic Competition Lawsuits? at Motley Fool
Nov-25-16 08:32AM  J&J (JNJ) Reportedly Approaches Actelion for Acquisition
Nov-21-16 01:19PM  5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them at Motley Fool
Nov-09-16 04:29PM  How Greater Washington stocks fared post-election at bizjournals.com +7.16%
07:27AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : November 9, 2016
Nov-08-16 05:35PM  Palo Alto Investorss Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns at Insider Monkey
Nov-04-16 01:17AM  Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns at Insider Monkey
Nov-01-16 05:54PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors Accesswire
Oct-31-16 05:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of United Therapeutics Corporation -- UTHR Accesswire
01:06PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
10:39AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016
Oct-28-16 09:58AM  United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss
Oct-27-16 03:46PM  Edited Transcript of UTHR earnings conference call or presentation 27-Oct-16 1:00pm GMT
02:55PM  United Therapeutics upping the ante on R&D spending at bizjournals.com
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
07:07AM  Q3 2016 United Therapeutics Corp Earnings Release - Before Market Open
06:20AM  United Therapeutics beats 3Q profit forecasts
06:07AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:07AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Third Quarter 2016 Financial Results PR Newswire
Oct-26-16 07:25PM  6 Undervalued Stocks Trading Below the Peter Lynch Value
12:41PM  ETFs with exposure to United Therapeutics Corp. : October 26, 2016
Oct-21-16 09:13AM  Is a Surprise Coming for United Therapeutics (UTHR) This Earnings Season?
Oct-20-16 06:00AM  United Therapeutics Corporation To Report Third Quarter 2016 Financial Results Before The Market Opens On Thursday, October 27, 2016 PR Newswire
Oct-14-16 03:31PM  Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation at Motley Fool
Oct-13-16 09:46AM  Will These 5 Drug Stocks Be Big Winners This Earnings Season?
Oct-11-16 01:50PM  10 LGBT CEOs Who Weren't Afraid To Come Out
Oct-10-16 08:11AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : October 10, 2016
Oct-07-16 12:22PM  6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
Oct-05-16 10:04AM  Top 5 Pharma stocks with strong earnings momentum. : October 5, 2016
Sep-29-16 10:19AM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : September 29, 2016
Sep-28-16 04:31PM  United Therapeutics Chilled On M&A Fever Amid Actelion, Bayer Rivalry
08:17AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : September 28, 2016
06:44AM  5 Stocks with Exciting Price-to-Book Ratios
Sep-27-16 11:24AM  UNITED THERAPEUTICS CORP Files SEC form 8-K/A, Regulation FD Disclosure
10:29AM  Top 5 Pharma stocks by value : September 27, 2016
08:11AM  3 Great Stocks You Can Buy on Sale at Motley Fool
08:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
Sep-22-16 10:35AM  Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential at 24/7 Wall St.
Sep-01-16 08:04AM  How Analysts See United Therapeutics Continued Performance
Aug-31-16 11:58AM  ETFs with exposure to United Therapeutics Corp. : August 31, 2016
11:04AM  Physician and Payer Relationships to Increase UTHRs Drug Access
10:05AM  United Therapeutics Makes Novel Technologies a Priority
08:05AM  United Therapeutics Research Efforts Key to Boosting Stock
Aug-30-16 06:04PM  $1 Billion Sales Target in Place for Tyvaso
04:04PM  Generic Competition Not a Threat to UTHRs Remodulin
02:30PM  Strong Growth Projected for UTHRs Hypertension Drugs
02:30PM  Why UTHR Trades at Lower Multiples Compared to Its Peers
Aug-22-16 12:13PM  United Therapeutics Hurt By Competitive Pressure
Aug-20-16 12:05PM  This Company Could Grow Organs in the Lab -- and It's Not Organovo Holdings at Motley Fool
Aug-12-16 01:09PM  Analysts Recommendations for Celgene and Its Peers in 2016
01:09PM  How Do Celgenes Valuation Multiples Compare to Its Peers?
Aug-10-16 06:00AM  United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-05-16 02:03PM  ETFs with exposure to United Therapeutics Corp. : August 5, 2016
Aug-04-16 10:14AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 4, 2016
Aug-03-16 06:44PM  These Five Stocks Show a Combination of Value and Growth
06:03PM  Worst Performance YTD: MasterCard, Lazard
03:29PM  5 Mid-Cap Stocks With Low Enterprise Multiples
11:04AM  Inside Amgens Analyst Recommendations for 2016
09:55AM  4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts at 24/7 Wall St.
Jul-28-16 09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today +5.11%
07:07AM  Q2 2016 United Therapeutics Corp Earnings Release - Before Market Open
06:34AM  United Therapeutics tops Street 2Q forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & CEOFeb 23Option Exercise30.751,20837,1461,348Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Option Exercise30.7596829,766646,302Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Sale145.161,208175,356140Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Option Exercise30.751,17336,0701,313Feb 17 04:54 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Option Exercise30.751,00430,873645,334Feb 17 04:54 PM
MAHON PAUL AEVP & General CounselFeb 16Option Exercise51.376,000308,22041,221Feb 17 04:55 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Sale167.921,173196,966140Feb 17 04:54 PM
ROTHBLATT MARTINE AChairman & CEOFeb 09Option Exercise30.751,17836,2241,318Feb 13 05:21 PM
ROTHBLATT MARTINE AChairman & CEOFeb 09Option Exercise30.7599830,689644,330Feb 13 05:21 PM
CAUSEY CHRISTOPHERDirectorFeb 02Option Exercise53.571,25066,9632,225Feb 03 04:14 PM
ROTHBLATT MARTINE AChairman & CEOFeb 02Option Exercise30.751,18136,3161,321Feb 03 04:17 PM
ROTHBLATT MARTINE AChairman & CEOFeb 02Option Exercise30.7599630,627643,332Feb 03 04:17 PM
MAHON PAUL AEVP & General CounselFeb 02Option Exercise51.376,000308,22041,221Feb 03 04:16 PM
ROTHBLATT MARTINE AChairman & CEOJan 26Option Exercise30.751,18636,4701,326Jan 27 05:29 PM
ROTHBLATT MARTINE AChairman & CEOJan 26Option Exercise30.7599030,443642,336Jan 27 05:29 PM
ROTHBLATT MARTINE AChairman & CEOJan 19Option Exercise30.751,19536,7461,335Jan 20 05:21 PM
ROTHBLATT MARTINE AChairman & CEOJan 19Option Exercise30.7598230,197641,346Jan 20 05:21 PM
MAHON PAUL AEVP & General CounselJan 19Option Exercise54.806,000328,78039,221Jan 23 04:12 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Option Exercise30.751,21437,3311,354Jan 12 04:30 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Option Exercise30.7596229,582640,364Jan 12 04:30 PM
PATUSKY CHRISTOPHERDirectorJan 12Option Exercise30.755,000153,7505,000Jan 12 04:32 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Sale142.371,214172,840140Jan 12 04:30 PM
PATUSKY CHRISTOPHERDirectorJan 12Sale141.995,000709,9690Jan 12 04:32 PM
MAHON PAUL AEVP & General CounselJan 05Option Exercise50.096,000300,54041,221Jan 06 04:05 PM
CAUSEY CHRISTOPHERDirectorJan 05Option Exercise53.571,25066,9631,715Jan 06 04:06 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Option Exercise30.751,20837,1461,348Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Option Exercise30.7596929,797639,402Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Sale145.731,208176,044140Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEODec 29Option Exercise30.751,21137,2381,351Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 29Option Exercise30.7596529,674638,433Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 29Sale143.631,211173,940140Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 22Option Exercise30.751,21837,4541,358Dec 23 11:39 AM
ROTHBLATT MARTINE AChairman & CEODec 22Option Exercise30.7595929,489637,468Dec 23 11:39 AM
ROTHBLATT MARTINE AChairman & CEODec 22Sale140.231,218170,800140Dec 23 11:39 AM
MAHON PAUL AEVP & General CounselDec 15Option Exercise50.096,000300,54041,221Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Option Exercise30.751,21237,2691,352Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Option Exercise30.7596429,643636,509Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Sale143.111,212173,446140Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Option Exercise30.751,23638,0071,376Dec 09 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Option Exercise30.7594128,936650,528Dec 09 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Sale131.781,236162,875140Dec 09 04:05 PM
Giltner RichardDirectorDec 06Option Exercise41.145,000205,7005,000Dec 07 04:20 PM
Giltner RichardDirectorDec 06Sale133.375,000666,8450Dec 07 04:20 PM
CAUSEY CHRISTOPHERDirectorDec 01Option Exercise51.771,25064,7131,855Dec 02 04:15 PM
ROTHBLATT MARTINE AChairman & CEODec 01Option Exercise30.751,24638,3151,386Dec 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEODec 01Option Exercise30.7593028,598649,587Dec 02 04:20 PM
MAHON PAUL AEVP & General CounselDec 01Option Exercise50.096,000300,54041,221Dec 02 04:19 PM
ROTHBLATT MARTINE AChairman & CEODec 01Sale126.861,246158,063140Dec 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEONov 25Option Exercise30.751,23337,9151,373Nov 29 04:07 PM
ROTHBLATT MARTINE AChairman & CEONov 25Option Exercise30.7594429,028648,657Nov 29 04:07 PM
ROTHBLATT MARTINE AChairman & CEONov 25Sale132.811,233163,749140Nov 29 04:07 PM
MAHON PAUL AEVP & General CounselNov 17Option Exercise50.096,000300,54041,221Nov 21 04:09 PM
ROTHBLATT MARTINE AChairman & CEONov 17Option Exercise30.751,23237,8841,372Nov 18 04:14 PM
ROTHBLATT MARTINE AChairman & CEONov 17Option Exercise30.7594429,028647,713Nov 18 04:14 PM
ROTHBLATT MARTINE AChairman & CEONov 17Sale132.941,232163,779140Nov 18 04:14 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:30 PM
ROTHBLATT MARTINE AChairman & CEONov 10Option Exercise30.751,24038,1301,380Nov 14 04:12 PM
ROTHBLATT MARTINE AChairman & CEONov 10Option Exercise30.7593728,813646,769Nov 14 04:12 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:28 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:31 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:43 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:30 PM
ROTHBLATT MARTINE AChairman & CEONov 10Sale129.821,240160,978140Nov 14 04:12 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:28 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:31 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:43 PM
MAHON PAUL AEVP & General CounselNov 03Option Exercise50.096,000300,54041,221Nov 04 04:04 PM
CAUSEY CHRISTOPHERDirectorNov 03Option Exercise51.771,25064,7131,855Nov 04 04:04 PM
ROTHBLATT MARTINE AChairman & CEONov 03Option Exercise30.751,27239,1141,412Nov 04 04:05 PM
ROTHBLATT MARTINE AChairman & CEONov 03Option Exercise30.7590427,798645,832Nov 04 04:05 PM
ROTHBLATT MARTINE AChairman & CEONov 03Sale116.941,272148,750140Nov 04 04:05 PM
ROTHBLATT MARTINE AChairman & CEOOct 27Option Exercise30.751,27239,1141,412Oct 28 04:02 PM
ROTHBLATT MARTINE AChairman & CEOOct 27Option Exercise30.7590527,829644,928Oct 28 04:02 PM
ROTHBLATT MARTINE AChairman & CEOOct 27Sale117.061,272148,905140Oct 28 04:02 PM
MAHON PAUL AEVP & General CounselOct 21Option Exercise50.096,000300,54041,221Oct 21 04:24 PM
ROTHBLATT MARTINE AChairman & CEOOct 20Option Exercise30.751,28239,4221,422Oct 21 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 20Option Exercise30.7589427,491644,023Oct 21 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 20Sale113.301,282145,249140Oct 21 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 13Option Exercise30.751,26939,0221,409Oct 17 04:08 PM
ROTHBLATT MARTINE AChairman & CEOOct 13Option Exercise30.7590827,921643,129Oct 17 04:08 PM
ROTHBLATT MARTINE AChairman & CEOOct 13Sale117.991,269149,736140Oct 17 04:08 PM
CAUSEY CHRISTOPHERDirectorOct 06Option Exercise51.771,25064,7132,355Oct 11 04:10 PM
MAHON PAUL AEVP & General CounselOct 06Option Exercise50.096,000300,54041,221Oct 11 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 06Option Exercise30.751,26038,7451,400Oct 07 04:07 PM
ROTHBLATT MARTINE AChairman & CEOOct 06Option Exercise30.7591628,167642,221Oct 07 04:07 PM
ROTHBLATT MARTINE AChairman & CEOOct 06Sale121.171,260152,679140Oct 07 04:07 PM
ROTHBLATT MARTINE AChairman & CEOSep 29Option Exercise30.751,27239,1141,412Sep 30 04:11 PM
ROTHBLATT MARTINE AChairman & CEOSep 29Option Exercise30.7590527,829641,305Sep 30 04:11 PM
ROTHBLATT MARTINE AChairman & CEOSep 29Sale116.941,272148,743140Sep 30 04:11 PM
Thompson Tommy GDirectorSep 26Option Exercise48.111,29162,1101,291Sep 27 05:01 PM
Thompson Tommy GDirectorSep 26Sale125.571,291162,1110Sep 27 05:01 PM
ROTHBLATT MARTINE AChairman & CEOSep 22Option Exercise30.751,24938,4071,389Sep 26 04:31 PM
ROTHBLATT MARTINE AChairman & CEOSep 22Option Exercise30.7592728,505640,400Sep 26 04:31 PM
ROTHBLATT MARTINE AChairman & CEOSep 22Sale125.871,249157,208140Sep 26 04:31 PM
MAHON PAUL AEVP & General CounselSep 15Option Exercise50.096,000300,54041,221Sep 19 10:35 AM
ROTHBLATT MARTINE AChairman & CEOSep 15Option Exercise30.751,25838,6841,398Sep 19 10:34 AM
ROTHBLATT MARTINE AChairman & CEOSep 15Option Exercise30.7591928,259639,473Sep 19 10:34 AM
ROTHBLATT MARTINE AChairman & CEOSep 15Sale122.341,258153,909140Sep 19 10:34 AM
ROTHBLATT MARTINE AChairman & CEOSep 08Option Exercise30.751,25438,5611,394Sep 09 04:06 PM
ROTHBLATT MARTINE AChairman & CEOSep 08Option Exercise30.7592228,352638,554Sep 09 04:06 PM